S.Korea's Celltrion jumps on contract to distribute COVID-19 test kits in U.S.

Celltrion Pharm

03/11/2020 02:30

** South Korea's biggest biopharmaceutical firm Celltrion
Inc  068270.KS  and its affiliates surge a day after signing a
210 billion won ($185.28 million) supply contract to distribute
its rapid COVID-19 testing kit Sampinute in the U.S.
 urn:newsml:reuters.com:*:nS6N2H400R
    ** Shares of Celltrion Inc jump for a second day and as much
as 5.1% to its highest since Oct. 19
    ** Its affiliates Celltrion Pharm Inc  068760.KQ  and
Celltrion Healthcare Co Ltd  091990.KQ  also rise as much as
3.8% and 4.5%, respectively
    ** The signing of contract comes a week after the co
received emergency use authorisation (EUA) from the U.S. Food &
Drug Administration (FDA) for Sampinute  urn:newsml:reuters.com:*:nL1N2HH03K
    ** The broader KOSPI market  .KS11  and junior KOSDAQ
 .KQ11  were trading up 1.8% and 2.2% each as of 0219 GMT
    
    ($1 = 1,133.4000 won)

 (Reporting by Joori Roh)
 ((joori.roh@thomsonreuters.com; +82 2 6936 1493;))